Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

TCT 2021 | Future of myeloma treatment

Ankit Kansagra • 8 Feb 2021
TCT 2021
Multiple Myeloma Antibodies CAR-T

Ankit Kansagra, MD, UT Southwestern Medical Center, Dallas, TX, discusses future directions in the treatment and management of multiple myeloma including novel immunotherapies such as CAR-T and bispecific antibody products in this field, as well as where these therapies fit in the treatment landscape of multiple myeloma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Ankit Kansagra

An analysis on patients with high-risk multiple myeloma
4:06
An analysis on patients with high-risk multiple myeloma
Ankit Kansagra • 16 Dec 2021
Autologous stem cell transplant for POEMS Syndrome
2:56
Autologous stem cell transplant for POEMS Syndrome
Ankit Kansagra • 16 Dec 2021
Real-world treatment patterns & outcomes of functional high-risk myeloma
4:36
Real-world treatment patterns & outcomes of functional high-risk myeloma
Ankit Kansagra • 8 Feb 2021
KarMMa: characterizing incidence of CRS in R/R myeloma
3:53
KarMMa: characterizing incidence of CRS in R/R myeloma
Ankit Kansagra • 8 Feb 2021

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Ankit Kansagra • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Ankit Kansagra • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Ankit Kansagra • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Ankit Kansagra • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals